The American Cancer Association estimates that 1.5 million citizens of the US are diagnosed with cancer each year. Approximately 50% of these cancer patients will undergo radiation therapy, which can provide definitive local regional tumor control, thus affording these patients with a durable progression free survival. Unfortunately, many tumors do not respond to irradiation. Elucidating the molecular mechanisms responsible for radiation therapy's failure to control tumor growth requires a critical understanding of Radiation Biology, a multi- disciplinary science that studies physics, biology, and medicine as it pertains to oncogenesis, tumor biology and normal tissue physiology. As important as Radiation Biology is for supporting Radiation Oncology's mission, there are very few such training programs in this country. The goal of this training grant is to continue to teach Postdoctoral Fellows to perform independent research in the area of Radiation Biology, so that they can make outstanding contributions to the fields of Radiation Oncology and Cancer Biology. We propose to accomplish this using a multi-faceted approach consisting of 1) training in the laboratories of outstanding scientists who utilize cutting edge techniques coupled with highly collaborative approaches, 2) multi- disciplinary seminar series designed to foster interactions between basic scientists and clinician/scientists who perform translational research, 3) didactic training in the areas of Radiation Biology, Radiation Physics, and Cancer Biology, 4) a grant writing workshop, 5) professional development, 6) training in laboratory management, and 7) Training in the Responsible Conduct of Research. Trainees must have completed a MD and/or a PhD prior to entering the program. The program is designed to train 3 Fellows for a duration ranging from 2 to 3 years. It is anticipated that 2 of the trainees will have just completed their PhD or MD and the third trainee will have 2 or 3 years Post Doctoral experience prior to entering our program. To date 70% of trainees who complete training tenure track assistant professors, staff scientists at pharmaceutical companies, or Radiation Oncology Residents on track to attain faculty positions. Of note, 30% of the trainees who have accepted offers to this program have been underrepresented minorities. Based on these successes, we submit that this training grant program is fulfilling the goals of the National Ruth L. Kirschstein National Research Service Award.

Public Health Relevance

Radiation oncology is an integral component of cancer therapy and radiation biology is the multi-disciplinary science used to identify and develop new radiation oncology therapies. Unfortunately, there is a lack of formal radiation biology training programs in this United States. This application seeks to continue its outstanding success in training MDs and PhDs in the field of radiation biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
6T32CA093240-15
Application #
9248767
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2001-12-01
Project End
2017-06-30
Budget Start
2016-05-01
Budget End
2016-06-30
Support Year
15
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Liu, Xiaojing; Cooper, Daniel E; Cluntun, Ahmad A et al. (2018) Acetate Production from Glucose and Coupling to Mitochondrial Metabolism in Mammals. Cell 175:502-513.e13
Kusunose, Jiro; Caskey, Charles F (2018) Fast, Low-Frequency Plane-Wave Imaging for Ultrasound Contrast Imaging. Ultrasound Med Biol 44:2131-2142
Traver, Geri; Mont, Stacey; Gius, David et al. (2017) Loss of Nrf2 promotes alveolar type 2 cell loss in irradiated, fibrotic lung. Free Radic Biol Med 112:578-586
Sorace, Anna G; Syed, Anum K; Barnes, Stephanie L et al. (2017) Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer. Mol Imaging Biol 19:130-137
Feeley, Kyle P; Adams, Clare M; Mitra, Ramkrishna et al. (2017) Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells. Cancer Res 77:3823-3833
Mont, Stacey; Davies, Sean S; Roberts Second, L Jackson et al. (2016) Accumulation of isolevuglandin-modified protein in normal and fibrotic lung. Sci Rep 6:24919
Layer, Justin H; Alford, Catherine E; McDonald, W Hayes et al. (2016) LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding. Mol Cell Biol 36:488-506
Sorace, Anna G; Quarles, C Chad; Whisenant, Jennifer G et al. (2016) Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results. Breast Cancer Res Treat 155:273-84
Mohni, Kareem N; Thompson, Petria S; Luzwick, Jessica W et al. (2015) A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PLoS One 10:e0125482
Carrillo, Alexia M; Hicks, Mellissa; Khabele, Dineo et al. (2015) Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells. Mol Cancer Res 13:1197-205

Showing the most recent 10 out of 40 publications